**Abbott**

# CardioMEMS™ HF System

## CLINICAL COMPENDIUM

The CardioMEMS™ HF System is the first and only FDA-approved heart failure monitor proven to significantly reduce heart failure hospital admissions and improve quality of life in NYHA Class III heart failure patients.[1]

When used by clinicians to manage heart failure, the CardioMEMS HF System is:

- Safe and reliable — demonstrated 98.6% freedom from device- or system-related complications.[1]

- Clinically proven — reduced heart failure admissions by 33%[1] and all-cause 30-day readmissions by 58%.[2]

- Proactive and personalized — patient management through direct monitoring of PA pressure and titration of medications.

Traditional physiologic markers in the development of acute decompensation in patients suffering from heart failure such as intrathoracic impedance, weight, blood pressure and symptoms are late and unreliable,[3,4] with only moderate sensitivity and specificity.[5-7] Large, randomized, controlled studies using telemonitoring of these indirect markers have failed to demonstrate a reduction in heart failure hospitalizations.[3,4,8] This clinical compendium summarizes key studies demonstrating the safety and effectiveness of the CardioMEMS HF System.

**What's New since the Last Update of April 2019?**

Lindenfeld J, et al. Hemodynamic-GUIDEd Management of Heart Failure (GUIDE-HF). *Am Heart J.* 2019;214:18-27.

Abraham J, et al. Association of Ambulatory Hemodynamic Monitoring with Clinical Outcomes in a Concurrent Matched Cohort Analysis. *JAMA Cardiology.* 2019;4(6):556-563.

Benza RL, et al. Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor. *Chest.* 2019; In press.

# Pre-CHAMPION

### VERDEJO HE, CASTRO PF, CONCEPCION R, FERRADA MA, ALFARO MA, ALCAINO ME, DECK CC, BOURGE RC. COMPARISON OF A RADIOFREQUENCY-BASED WIRELESS PRESSURE SENSOR TO SWAN-GANZ‡ CATHETER AND ECHOCARDIOGRAPHY FOR AMBULATORY ASSESSMENT OF PULMONARY ARTERY PRESSURE IN HEART FAILURE

*J Am Coll Cardiol.* 2007;50:2375-2385.

The CardioMEMS™ HF System monitors PA pressure measurements from a sensor implanted into the PA. The safety and accuracy of the CardioMEMS™ PA Sensor have been demonstrated in previous studies.[9,10] Systolic and diastolic PA pressures were significantly correlated between the CardioMEMS PA Sensor and traditional Swan-Ganz‡ catheter measurements and between the CardioMEMS PA Sensor and standard echocardiography.[9,10]

### CASTRO PF, CONCEPCION R, BOURGE RC, MARTINEZ A, ALCAINO M, DECK C, FERRADA M, ALFARO M, PERRONE S. A WIRELESS PRESSURE SENSOR FOR MONITORING PULMONARY ARTERY PRESSURE IN ADVANCED HEART FAILURE: INITIAL EXPERIENCE

*J Heart Lung Transplant.* 2007;26:85-88.

Device implantation was simple and the sensor accurately measured PA pressure. No complications were observed and there was no evidence of PA thrombosis at 60 days. Diuretic and vasodilator doses were increased and the patient improved without further heart failure-related hospitalization.

### ADAMSON PB, ABRAHAM WT, AARON M, ARANDA JM, BOURGE RC, SMITH A, STEVENSON LW, YADAV J. CHAMPION TRIAL RATIONALE AND DESIGN: THE LONG-TERM SAFETY AND CLINICAL EFFICACY OF A WIRELESS PULMONARY ARTERY PRESSURE MONITORING SYSTEM

*J Card Fail.* 2010;17:3-10.

The CHAMPION clinical trial investigated the safety and clinical efficacy of the CardioMEMS HF System and established this management strategy as a new paradigm for the medical management of patients with symptomatic heart failure.

### ABRAHAM WT, ADAMSON PB, HASAN A, BOURGE RC, PAMBOUKIAN SV, AARON MF, RAVAL NY. SAFETY AND ACCURACY OF A WIRELESS PULMONARY ARTERY PRESSURE MONITORING SYSTEM IN PATIENTS WITH HEART FAILURE

*American Heart Journal.* 2011;161:558-566.

The safety and accuracy of the CardioMEMS PA Sensor have been demonstrated in previous studies.[9,10] Systolic and diastolic PA pressures were significantly correlated between the CardioMEMS PA Sensor and traditional Swan-Ganz catheter measurements and between the CardioMEMS PA Sensor and standard echocardiography.[9,10]

A feasibility study reported the safe and successful implantation of the CardioMEMS PA Sensor in a clinical setting with no serious device-related events (n = 17).[10]

## CHAMPION

### WIRELESS PULMONARY ARTERY HAEMODYNAMIC MONITORING IN CHRONIC HEART FAILURE: A RANDOMISED CONTROLLED TRIAL

Abraham, et al. *The Lancet.* 2011.[1]

- The aim of this randomized, multicenter, single-blind, controlled study was to evaluate the safety of the system and the efficacy of PA pressure-guided therapy on heart failure hospitalizations:
  - NYHA Class III heart failure patients irrespective of left ventricular EF and who had been hospitalized for heart failure within the past 12 months were implanted with the CardioMEMS PA Sensor (n = 550); patients were randomized to either the treatment group (heart failure management guided by PA pressure measurements; n = 270) or the control group (SOC management; n = 280).
- Mean follow-up time was 15 months.
- Both primary safety and efficacy endpoints were met:
  - Patients had a 98.6% freedom from device- or system-related complications (95% CI 97.3 to 99.4) with no pressure-sensor failures (95% CI 99.3 to 100.0).
  - The rate of heart failure hospitalizations at six months was reduced by 28% in the treatment group (p = 0.0002).
- During the first six months of follow-up, compared to the control group, the treatment group had:
  - A greater reduction in PA pressure (-156 vs. 33 mean AUC; p < 0.008).
  - Fewer patients admitted to the hospital for heart failure (20% treatment group vs. 29% control group; p < 0.03).
  - More days alive outside of the hospital (174.4 ± 31.1 vs. 172.1 ± 37.8 days; p < 0.02).
  - Better patient quality of life (45 ± 26 vs. 51 ± 25; p = 0.02 based on Minnesota Living with Heart Failure Questionnaire).

**KEY TAKEAWAYS:**

- The treatment group required < 1 medication change per patient per month compared to the control group (9.1 ± 7.4 vs. 3.8 ± 4.5 changes per patient during the first six months of follow-up; p < 0.0001).

- During the entire follow-up (mean 15 months), PA pressure-guided therapy (treatment group) significantly reduced heart failure hospitalizations by 37% compared to the control group (p < 0.0001; **Figure 1**).

- The treatment group had a lower risk of death or freedom from first heart failure hospitalization during the entire follow-up period compared to the control group (p = 0.0086).

**Figure 1.** Cumulative heart failure hospitalizations during the entire period of follow-up



| | ≤ 6 Months 28% RRR p < 0.0002 | > 6 Months 45% RRR p < 0.0001 | Study Duration 37% RRR p < 0.0001 |

Control — 254 Heart Failure Hospitalizations

Treatment — 158 Heart Failure Hospitalizations

HR 0.63 (95% CI 0.52–0.77) p < 0.0001

| No. at Risk | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| Control | 280 | 267 | 252 | 215 | 179 | 137 | 105 | 67 | 25 | 10 | 0 |
| Treatment | 270 | 262 | 244 | 210 | 169 | 131 | 108 | 82 | 29 | 5 | 1 |

Abraham WT, et al. *The Lancet*. 2011.[1]

**SUSTAINED EFFICACY OF PULMONARY ARTERY PRESSURE TO GUIDE ADJUSTMENT OF CHRONIC HEART FAILURE THERAPY (CHAMPION): COMPLETE FOLLOW-UP RESULTS FROM THE CHAMPION RANDOMISED TRIAL**

Abraham, et al. *The Lancet*. 2016.[11]

- This CHAMPION clinical trial analysis evaluated the impact on heart failure hospitalizations of the introduction of PA pressure monitoring in the control group (n = 170) of patients and continued PA monitoring in the treatment group (n = 177) during the open access phase of the trial.

- Following completion of the randomized access period (mean follow-up of 18 months), all patients were managed utilizing PA pressure monitoring with the CardioMEMS™ HF System (mean follow-up of 13 months) and evaluated in a longitudinal analysis.

- New access to PA pressures in the control group resulted in a 48% reduction in heart failure hospitalization rates (0.36 vs. 0.68; HR 0.52; 95% CI 0.40 to 0.69; p < 0.0001; **Figure 2**).

- The low heart failure hospitalization rate in the treatment group during the randomized access period was maintained in the open access period (0.45 vs. 0.48; HR 0.93; 95% CI 0.70 to 1.22; p = 0.5838; **Figure 2**).

**KEY TAKEAWAYS:**

- The longitudinal analysis confirms the effectiveness of the CardioMEMS HF System and supports the findings from the randomized portion of the CHAMPION clinical trial.

- Even after adjustment for longitudinal confounders, new access to PA pressure monitoring for the formerly blinded control group resulted in a significant reduction in heart failure hospitalizations.

**Randomized and Open Access Periods Also Led to Significant Reduction in Heart Failure Hospitalization**

**Figure 2. Part 1:** Randomized access and **Part 2:** Open access

**Treatment and Former Treatment**



Randomized Access — 0.48

Open Access — 0.45

Sustained Low Heart Failure Hospitalization Rate*

**Control and Former Control**



Randomized Access — 0.68

New Access to PA Pressure

Open Access — 0.36

**48%** Reduction in Heart Failure Hospitalization

Results from the open access period **confirm the effectiveness** of the CardioMEMS™ HF System observed during the random access period.

*Over 31 months, despite termination of sponsor communications.
Abraham W, et al. *The Lancet*. 2016.

# Preplanned (Prospective) CHAMPION Subgroup Analyses

**EFFECTS OF PA PRESSURE MONITORING ON HFpEF SUBGROUP**

**WIRELESS PULMONARY ARTERY PRESSURE MONITORING GUIDES MANAGEMENT TO REDUCE DECOMPENSATION IN HEART FAILURE WITH PRESERVED EJECTION FRACTION**

Adamson, et al. *Circulation Heart Fail.* 2014.[12]

- This subanalysis of the CHAMPION clinical trial evaluated the effect of PA pressure-guided therapy with the CardioMEMS™ HF System in NYHA Class III patients with preserved ejection fraction (HFpEF).
- Of the HFpEF patients (n = 119), 62 were randomized to the treatment group (PA pressure-guided therapy) and 57 to the control group (SOC).

**KEY TAKEAWAY:**

- PA pressure-guided therapy significantly reduced heart failure hospitalizations for HFpEF patients in the treatment group by 50% compared to those patients in the control group, with an average follow-up time of 30 months (p < 0.0001). Results were associated with a rate of 0.43 events/patient-year in the treatment group vs. 0.86 events/patient-year in the control group **(Figure 3)**.

**Prospective Subgroup Analysis: HFpEF Patients Managed with the CardioMEMS™ HF System Show Significant Reduction in Heart Failure Hospitalization**

**Figure 3.**



**EFFECTS OF PA PRESSURE MONITORING ON HFrEF SUBGROUP, HFrEF SUBGROUP ALREADY ON GDMT**

**PULMONARY ARTERY PRESSURE-GUIDED MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION**

Givertz, et al. *J Am Coll Cardiol.* 2017.[13]

Initiation of a PA pressure-guided heart failure management strategy, even in HFrEF patients receiving optimal background medical and device therapy, was able to achieve large, consistent reductions in heart failure hospitalization and mortality in HFrEF patients enrolled in the CHAMPION trial.

**KEY RESULTS:**

**Prospective Study Results**

- In the CHAMPION HFrEF cohort, heart failure hospitalization rates were **28% lower** than control **(p = 0.0013)**; mortality was **32% lower**, trending toward significance **(p = 0.06)** at 18 months **(Figure 4 and Figure 5)**.

**Prospective Subgroup Analysis: HFrEF Patients Show Significant Reduction in Heart Failure Hospitalization and Strong Trend Toward Improved Survival**

**Figure 4.** Clinical outcomes



**Figure 5.** Survival probability



| No. at Risk | | | | | | | |
|---|---|---|---|---|---|---|---|
| Control | 234 | 209 | 173 | 102 | 45 | 7 | 0 |
| Treatment | 222 | 202 | 161 | 105 | 62 | 7 | 0 |

Kaplan-Meier Survival Analysis

## RETROSPECTIVE STUDY DESCRIPTION:

This paper also included a retrospective analysis of the CHAMPION HFrEF cohort (n = 456), based on strong indicators for reduced heart failure hospitalization and mortality in the prospective subgroup analysis of HFrEF patients.

This study addresses the hypothesis that hemodynamic-guided care benefits patients even if they are already on maximum GDMT.

Evaluated heart failure hospitalizations and mortality based on patients' ability to tolerate full GDMT vs. incomplete medical therapy.

**Figure 6.** Partial GDMT



**Figure 7.** "Max" GDMT



## KEY RESULTS:

- In the CHAMPION HFrEF population (prospective subgroup analysis), heart failure hospitalization rates were 28% lower than control (p = 0.0013) and mortality was 32% lower, trending toward significance (p = 0.06).

- Because there was such a strong signal for improved survival in the prospective study, a retrospective study was done on the CHAMPION HFrEF subgroup, splitting them into groups based on the ability to tolerate GDMT:

  - **Group 1** (n = 455)**: tolerated at least one ACEI/ARB and/or BB.**

  - **Group 2** (n = 337)**: tolerated both ACEI/ARB and BB.**

- Heart failure hospitalization in Group 1 was 33% lower than control (p = 0.0002) (left panel, left points).

- Heart failure hospitalization in Group 2 was 43% lower than control (p < 0.0002) (left panel, right points).

- Mortality in Group 1 was 37% lower than control (p = 0.0293) (right panel, left points).

- Mortality in Group 2 was 57% lower than control (p = 0.0052) (right panel, right points).

## CONCLUSION:

- PA pressure-guided heart failure management strategy resulted in significant reductions in hospitalizations and mortality in patients receiving prior optimal GDMT.

- Maximally tolerated GDMT at target doses is very important to control heart failure disease progression. There is apparent synergy between GDMT and hemodynamic monitoring in the control of heart failure disease progression.

- This retrospective analysis suggests the impact of GDMT on mortality and heart failure progression is significantly enhanced by avoiding decompensation events using guidance from the CardioMEMS™ HF System.

# Retrospective Subanalyses

**CARDIOMEMS™ HF SYSTEM-GUIDED PA PRESSURE MONITORING PROVIDED ACTIONABLE INFORMATION AND A MORE PERSONALIZED PHARMACOLOGICAL APPROACH, SO CLINICIANS COULD BETTER MANAGE HF**

## EFFECT OF CRT ON HEART FAILURE RELATED HOSPITALIZATIONS IN PATIENTS WITH REDUCED EF UTILIZING REMOTE PULMONARY ARTERY PRESSURES IN THE CHAMPION TRIAL

Weiner S, et al. *Heart Rhythm*. 2011.[14]

- This subanalysis of the CHAMPION clinical trial evaluated the effect of PA pressure-guided therapy with the CardioMEMS™ HF System in patients with rEF (rEF < 40%; n = 430) with and without a CRT device.
- 40% (171 of 430) of rEF patients had CRT devices; of this cohort, 82 patients were in the treatment group and 89 in the control group.
- 60% (259 of 430) of rEF patients did not have CRT devices; of this cohort, 126 patients were in the treatment group and 42 in the control group.

**KEY TAKEAWAY:**

- Remote PA pressure data in the treatment group resulted in similar reductions in heart failure hospitalization in patients with and without a CRT device, suggesting that heart failure management guided by PA pressures may provide additive benefits to CRT therapy:
  - For patients in the rEF-CRT group, those who received PA pressure-guided therapy had significantly fewer heart failure hospitalizations (RRR = 24%; p = 0.0264).
  - For patients in the rEF-no CRT group, PA pressure-guided therapy resulted in a RRR = 23%.

## THE UTILITY OF REMOTE WIRELESS PULMONARY ARTERY PRESSURE MONITORING IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION: EXPERIENCE FROM THE CHAMPION TRIAL

Strickland WL, et al. *JACC*. 2011.[15]

- This subanalysis of the CHAMPION clinical trial determined whether PA pressure monitoring affected the clinical outcomes of patients with and without a history of MI.
- 271 of the 550 NYHA Class III heart failure patients enrolled in the CHAMPION clinical trial had a history of MI and were randomized to either the control (n = 137) or treatment (n = 134) groups.
- At six months, there was a 2.2-day benefit of days alive outside the hospital for patients in the treatment group; at 15 months, this increased to 30.1 days.

**KEY TAKEAWAY:**

- At six months and for the full study duration (mean 15 months), remote PA pressure monitoring had a significant reduction in heart failure hospitalizations for patients with and without a history of MI in the treatment group vs. control **(Table 1)**.

**Table 1.** RRR of heart failure hospitalizations

|  | RRR at 6 Months for Treatment Group | RRR at 15 Months for Treatment Group |
|---|---|---|
| History of MI | 30% (p < 0.0039 vs. control) | 46% (p < 0.0001 vs. control) |
| No MI | 25% (p = 0.016 vs. control) | 23% (p = 0.021 vs. control) |

## IMPACT OF REMOTE, WIRELESS PULMONARY ARTERY HEMODYNAMIC MONITORING IN PATIENTS WITH ATRIAL FIBRILLATION AND CHRONIC HEART FAILURE: INSIGHTS FROM THE CHAMPION TRIAL

Miller, et al. *JACC*. 2012.[16]

- This CHAMPION clinical trial subanalysis compared the baseline characteristics and impact of PA pressure-guided therapy on hospitalization rates in patients with a history of AF (n = 255) compared to those with normal sinus rhythm (n = 200).
- The AF cohort had significant baseline differences compared to the sinus rhythm cohort (older: 65 vs. 59; more often male):
  - 80% vs. 66%, more frequently had CRT or CRT-D devices.
  - 44% vs. 27%, higher mean PA pressures: 30.2 vs. 28.5 mmHg, etc.

**KEY TAKEAWAYS:**

- AF patients in the treatment group had a significantly lower heart failure hospitalization rate than those in the control group at six months (37%; p = 0.0004) and 15 months (41%; p < 0.0001).

AF patients had a 57% higher heart failure hospitalization rate vs. non-AF patients (0.47 vs. 0.30 events/patient; p < 0.0001).

## TARGETING PULMONARY ARTERY PRESSURES IN THE TREATMENT OF CHRONIC HEART FAILURE: INSIGHTS FROM THE CHAMPION TRIAL

Adamson, et al. *European Heart Journal*. 2012.[17]

- This CHAMPION clinical trial subanalysis determined whether remote access to PA pressure data may provide a method to identify and treat high filling pressures in heart failure patients at increased risk for decompensation (n = 550).
- At implant, the mean PA pressure was similar in both control and treatment groups (31.8 ± 10.7 mmHg and 31.3 ± 11.1 mmHg, respectively).

- Average PA pressures increased during the six weeks prior to heart failure hospitalizations in both groups (p < 0.0001) and decreased significantly after successful in-hospital decongestion (p < 0.0001).

- Treatment patients with heart failure hospitalizations had lower pressures compared to control patients with heart failure hospitalizations at all time points prior to hospitalization:

  - Treatment patients also had lower PA pressures compared to the control patients regardless of hospitalization type (heart failure related or non-heart failure related).

**KEY TAKEAWAYS:**

- Higher PA pressures and increases in PA pressure were both associated with increased risk for heart failure hospitalizations.

- Heart failure treatment strategies that target both high PA pressure and increases in PA pressures may be effective strategies for lowering the risk of decompensation in chronic heart failure patients.

### BENEFITS OF PULMONARY ARTERY PRESSURE MONITORING IN PATIENTS WITH NYHA CLASS III HEART FAILURE AND CHRONIC KIDNEY DISEASE: RESULTS FROM THE CHAMPION TRIAL

Abraham, et al. *J Card Failure*. 2014.[18]

This subgroup data analysis from the CHAMPION clinical trial compared heart failure hospitalizations between NYHA Class III heart failure patients with CKD monitored (mean follow-up of 18 months) with PA pressure (n = 150) to those managed with SOC (n = 147):

- When CKD patients were managed with PA pressures, heart failure hospitalization rates were significantly reduced (42%) compared to patients with CKD managed according to SOC (0.48 vs. 0.83; HR 0.58; p < 0.001).

- Changes in CKD indicators (creatinine and glomerular filtration rates) were not adversely affected in the PA pressure-monitored group.

**KEY TAKEAWAYS:**

- CKD in patients with heart failure is a frequent comorbidity that is associated with worse clinical outcomes, including higher heart failure hospitalization rates.

- For heart failure patients with CKD, PA pressure monitoring reduced heart failure hospitalizations by 42% compared to SOC heart failure management.

- Intensified heart failure medical therapy as a result of PA pressure monitoring was safe and did not adversely affect renal function.

### PULMONARY HYPERTENSION RELATED TO LEFT HEART DISEASE: INSIGHT FROM A WIRELESS IMPLANTABLE HEMODYNAMIC MONITOR

Benza, et al. *JHLT*. 2015.[19]

This CHAMPION clinical trial subanalysis evaluated the effect of PA pressure monitoring in heart failure patients with comorbid PH (mean PA pressure > 25 mmHg):

- Data were obtained for 314 patients (59%) who had WHO Group II PH. Patients in the PH cohort were further stratified by TPG and pulmonary vascular resistance.

- 67% (213 out of 314) of PH patents had a TPG ≤ 15.

- Patients without PH were at significantly lower risk for mortality than PH patients (HR 0.31; 95% CI 0.19 to 0.52; p < 0.0001).

- PH patients had higher heart failure hospitalization rates than non-PH patients (0.77/year vs. 0.37/year; HR 0.49; 95% CI 0.39 to 0.61; p < 0.001).

- In patients with and without PH, ongoing knowledge of hemodynamic data resulted in a reduction in heart failure hospitalization for PH patients (HR 0.64; 95% CI 0.51 to 0.81; p = 0.002) and for non-PH patients (HR 0.60; 95% CI 0.41 to 0.89; p = 0.01).

- Among PH patients, there was a reduction in the composite endpoint of death and heart failure hospitalization with ongoing knowledge of hemodynamics (HR 0.74; 95% CI 0.55 to 0.99; p = 0.04), but no difference in survival (HR 0.78; 95% CI 0.50 to 1.22; p = 0.28).

**KEY TAKEAWAY:**

- PH patients are at a high risk for adverse outcomes. Ongoing knowledge of hemodynamic variables may allow more effective treatment strategies to reduce the morbidity of the disease.

### HEART FAILURE AND RESPIRATORY HOSPITALIZATIONS ARE REDUCED IN HEART FAILURE SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING AN IMPLANTABLE PULMONARY ARTERY PRESSURE MONITORING DEVICE

Krahnke, et al. *J Card Fail*. 2015.[20]

The purpose of this CHAMPION clinical trial subanalysis was to evaluate whether PA pressure-guided therapy reduced heart failure hospitalizations and REHs in a cohort of patients with comorbid COPD (n = 187).

**KEY TAKEAWAYS:**

- There was an overall reduction in PA pressures; patients in the treatment group (n = 91) had an average AUC reduction of 202 mmHg days compared to the increase of 107 mmHg days in the control group (n = 96; p = 0.03).

- At 15 months, there was a 41% reduction in heart failure hospitalization rates in the treatment group vs. the control group (0.55 vs. 0.96; HR 0.59; 95% CI 0.44 to 0.81; p = 0.0009).

- At 15 months, patients in the treatment group (n = 91) had a 62% reduction in REH (0.12 vs. 0.31; HR 0.38; 95% CI 0.21 to 0.71; p = 0.0023).

## LIMITATIONS OF RIGHT HEART CATHETERIZATION IN THE DIAGNOSIS AND RISK STRATIFICATION OF PATIENTS WITH PULMONARY HYPERTENSION RELATED TO LEFT HEART DISEASE: INSIGHTS FROM A WIRELESS PULMONARY ARTERY PRESSURE MONITORING SYSTEM

Raina, et al. *JHLT*. 2015.[21]

- This CHAMPION sub-study compared the use of the CardioMEMS™ HF System with RHC to diagnose and stratify risk in patients with PH.

- RHC identified 320 patients with PH (defined as mean PA pressure > 25 mmHg) and among these patients mean PA pressure obtained from RHC was similar to the CardioMEMS HF System's first-week PA pressure.

- RHC also identified 217 patients without PH (defined as mean PA pressure readings ≤ 25 mmHg) and 51% of them met this definition according to data obtained from the CardioMEMS HF System (18.5 for the RHC vs. 18.4 for the CardioMEMS HF System, p = 0.9208).

- The other 49% of patients identified by RHC as not having PH had first-week mean PA pressure readings > 25 mmHg with the CardioMEMS HF System, indicating PH.

- Among the 217 patients using the CardioMEMS HF System diagnosed by RHC as non-PH, the 49% with first-week mean PA pressure readings > 25 mmHg had significantly higher heart failure hospitalization rates than the 51% of patients with readings ≤ 25 mmHg (0/49 vs. 0.25/year, p = < 0.0001).

**KEY TAKEAWAYS:**

- This analysis suggests that using RHC alone may result in PH underdiagnoses in patients with heart failure.

- In this study, the more frequent PA pressure monitoring with the CardioMEMS HF System provided better diagnostic and risk stratification compared with single RHC.

**THERAPY GUIDED BY PA PRESSURE ALONE VS. SIGNS AND SYMPTOMS**

## PRESSURE FOR ACTION: IMPLANTABLE PULMONARY ARTERY PRESSURE SENSOR MEASUREMENTS ALONE BEAT CLINICAL SIGNS TO GUIDE PREVENTION OF HEART FAILURE HOSPITALIZATIONS

Goldberg LR, et al. HRS 2015 Abstract AB36-02.[22]

- Data analysis from the CHAMPION clinical trial during the six-month primary endpoint period:
  - 550 patients: 270 in the treatment group and 280 in the control group.

- All interventions for patients in the PA pressure-managed group were characterized prospectively by investigators as triggered primarily by clinical findings OR by changes in PA pressure.

- Heart failure hospitalization rates were lowest in patients for whom all diuretic interventions were triggered by PA pressure (0.39 events/patient-year), despite this cohort having the highest baseline PA pressure **(Figure 8)**.

- There was a statistically significant 67% RRR of heart failure hospitalizations if a patient's diuretic interventions were managed with PA pressure alone vs. clinical signs only (HR 0.33; 95% CI 0.16 to 0.59; p = 0.0007).

- Medication changes based on PA pressure information were more effective in reducing heart failure hospitalizations than using signs and symptoms alone.

**Figure 8.** Heart failure hospitalization rate (events/year)



Managing medical therapy based on PA pressures, along with follow-up lab and patient assessments, led to **significantly better outcomes than managing based on clinical signs and symptoms.**

**KEY TAKEAWAYS:**

- Heart failure hospitalization rates (events/patient-year) were significantly reduced if a patient's diuretic management therapies were managed by:
  - PA pressure only compared to clinical signs (67% reduction).
  - PA pressure and clinical signs compared to clinical signs (46% reduction).

- Heart failure hospitalization rates were most effectively reduced by a management strategy based on PA pressures without reliance on clinical changes.

- This supports the strategy of early intervention prior to clinical signs to avert clinical decompensation and heart failure readmissions.[1,2]

**CONCLUSION:**

Managing medical therapy based on PA pressures, along with follow-up lab and patient assessments, led to significantly better outcomes than managing based on clinical signs and symptoms.

## INTERVENTIONS LINKED TO DECREASED HEART FAILURE HOSPITALIZATIONS DURING AMBULATORY PULMONARY ARTERY PRESSURE MONITORING

Costanzo, et al. *J Am Coll Cardiol Heart Fail.* 2016.[23]

**Figure 9.** Frequency of medication changes by drug class



- Medication changes based on PA pressure information were more effective in reducing heart failure hospitalizations than using signs and symptoms alone.

**Figure 10.**



*p < 0.05 PA Pressure-guided Heart Failure Management vs. SOC Heart Failure Management.
 No change represents where a medication was changed (e.g., dose frequency, route) that resulted in no net dose equivalent change.

## MEDICATION INCREASES AND DECREASES IN RESPONSE TO PA PRESSURE:

- Knowledge of ambulatory PA pressures leads to more interventions that reduce heart failure events compared with standard clinical assessment.

- The current study is focused on the degree and nature of the interventions made.

- Most medication interventions in CHAMPION were adjustments in diuretics.

- It is not known when vasodilators would be more effective than diuretics to maintain lower filling pressures. Neither is it known how titration of ACEIs/ARBs and BBs should be modulated by knowledge of ambulatory filling pressures that are too high or too low.

- The current analysis validates the target pressure ranges and the algorithm for intervention that can be used as a starting point to reduce heart failure hospitalizations and improve patient outcomes in previously hospitalized NYHA Functional Class III patients.

## MEDICARE-ELIGIBLE POPULATIONS

### PULMONARY ARTERY PRESSURE-GUIDED HEART FAILURE MANAGEMENT REDUCES 30-DAY READMISSIONS

Adamson, et al. *Circulation: Heart Failure.* 2016.[2]

- This data analysis from the CHAMPION clinical trial evaluated 30-day readmissions and heart failure hospitalizations between patients monitored with the CardioMEMS™ HF System and those not monitored over a period of 18 months.

- 245 patients were included in the analysis: 120 in the PA pressure treatment group and 125 in the SOC control group.

- In this analysis, patients managed with PA pressure compared to those managed according to SOC experienced:

  - 58% reduction in all-cause 30-day readmissions (0.07 vs. 0.18; HR 0.42; p = 0.0062).*

  - 78% reduction in heart failure 30-day readmissions (0.02 EPPY vs. 0.10 EPPY; HR 0.22; p = 0.0027).*

  - 49% reduction in heart failure hospitalizations (0.34 EPPY vs. 0.67 EPPY; HR 0.51; p < 0.0001).*

*Event rates are based on events/patient-year.

### KEY TAKEAWAYS:

- This retrospective analysis of the CHAMPION clinical trial demonstrated that PA pressure-guided management of Medicare-eligible heart failure patients significantly reduced 30-day readmissions, which may help to alleviate the economic burden associated with heart failure readmissions.

- This analysis supports results from the CHAMPION clinical trial demonstrating a 37% reduction in heart failure hospitalizations and improved quality of life with PA pressure-guided heart failure management in NYHA Class III heart failure patients irrespective of Medicare eligibility.[1]

**Figure 11.** Subgroup analysis: Medicare-eligible population shows significant reduction in 30-day readmissions



**Statistically significant reductions** in 30-day readmission and heart failure hospitalization in Medicare-eligible patients 65 years or older (n = 245), when PA pressures are monitored using the CardioMEMS™ HF System.

Adamson, et al. *Circ Heart Fail.* 2016.

## PULMONARY ARTERY PRESSURE-GUIDED MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

Givertz, et al. *J Am Coll Cardiol.* 2017.[13]

## HEART FAILURE PATIENTS WITH COMMON COMORBIDITIES

PA Pressure-guided Therapy Has Been Shown to Consistently Reduce Heart Failure Hospitalizations in Patients with Common Heart Failure Comorbidities

Heart failure is often associated with a variety of comorbidities such as respiratory disease, coronary artery disease and AF. These comorbidities contribute to disease progression and may alter the response to treatment.[24] This section highlights additional subanalyses from the CHAMPION clinical trial that consistently show that PA pressure-guided therapy reduces heart failure hospitalizations in patients with common heart failure comorbidities. **Table 2** summarizes the rate of heart failure hospitalizations across the different studies.

**The CHAMPION Trial Subgroup Analyses: Reduction of Heart Failure Hospitalization in Patient Groups with Common Comorbidities**

**Table 2.** Patients with common heart failure comorbidities have consistent reduction in heart failure hospitalizations with PA pressure-guided therapy

| Subgroup or Comorbidity | n (control) | n (treatment) | Follow-up Period (months) | Reduction of Heart Failure Hospitalization Rate in Treatment Group vs. Control Group |
|---|---|---|---|---|
| Medicare population[2] | 125 | 120 | 18 | 49%, $p < 0.0001$ |
| HFpEF[12] | 56 | 59 | 18 | 50%, $p < 0.0001$ |
| HFrEF following GDMT[13] | 174 | 163 | 17 | 43%, $p < 0.0001$ |
| CRT-D or ICD following GDMT[25] | 146 | 129 | 18 | 43%, $p < 0.0001$ |
| History of MI[20] | 137 | 134 | 15 | 46%, $p < 0.001$ |
| COPD[26,27] | 96 | 91 | 15 | 41%, $p = 0.0009$ |
| Pulmonary hypertension[28] | 163 | 151 | 15 | 36%, $p = 0.0002$ |
| AF[18] | 135 | 120 | 15 | 41%, $p < 0.0001$ |
| CKD[19] | 150 | 147 | 15 | 42%, $p = 0.0001$ |

Patients with common heart failure comorbidities and patents in important subgroups **have consistent reduction in heart failure hospitalizations** with PA pressure-guided therapy.

## THE UTILITY OF A WIRELESS IMPLANTABLE HEMODYNAMIC MONITORING SYSTEM IN PATIENTS REQUIRING MECHANICAL CIRCULATORY SUPPORT

Feldman D, et al. *ASAIO.* 2018.[28]

- This subanalysis of the CHAMPION clinical trial evaluated the effect of PA pressure-guided therapy on optimizing medications, pump parameters and timing of VAD intervention and transplantation in patients receiving an LVAD (n = 27).

**KEY TAKEAWAY:**

- LVAD patients who received PA pressure-guided therapy (15 out of 27 patients) had significantly shorter times to VAD intervention (p = 0.001), more changes to medical therapy based on hemodynamic information (p = 0.025) and shorter times between VAD intervention and heart transplantation (p = 0.001).

# The CardioMEMS™ HF System Commercial Experience: Results from Real-world Studies

## HEMODYNAMIC-GUIDED HEART-FAILURE MANAGEMENT USING A WIRELESS IMPLANTABLE SENSOR: INFRASTRUCTURE, METHODS, AND RESULTS IN A COMMUNITY HEART FAILURE DISEASE-MANAGEMENT PROGRAM

Jermyn R, et al. *Clin Cardiol.* 2016.[29]

**KEY TAKEAWAY:**

• Hemodynamic-guided heart failure management leads to significant improvements in NYHA Class and heart failure hospitalization rate in a small single-center study in a real-world setting, compared with usual care delivered in a comprehensive disease-management program:

– Three-fold greater improvement in KCCQ scores.

– Increase in 6MWD: Average increase of 96 meters at 90 days vs. no increase in the SOC group.

## IMPACT OF PRACTICE-BASED MANAGEMENT OF PA PRESSURES IN 2000 PATIENTS IMPLANTED WITH THE CARDIOMEMS SENSOR

Heywood, et al. *Circulation.* 2017.[30]

Observational Study from the First 2000 Commercially Implanted Patients from the **Merlin.net™** Patient Care Network Database

---

**Post-approval Observational Study of the CardioMEMS™ HF System Large (N = 2000) Observational Study from the First 2000 Commercially Implanted Patients**

**Figure 12.** Transmissions compliance



**Patients consistently upload pressures:**
Median 1.2 days between transmissions

Heywood JT, Jermyn R, Shavelle D, et al. *Circulation.* 2017;135:1509-17.



**Providers consistently treat pressures:**
Larger treatment effect in the real-world than CHAMPION

## PATIENTS' PRESSURE REDUCTION STRATIFIED BY EF AND BY GENDER

### Pressures Are Reduced Equally Well in HFrEF and HFpEF, as Well as Male and Female

**Figure 13.** AUC mean PA pressure stratified by EF

**Figure 14.** AUC mean PA pressure stratified by gender



Heywood JT, Jermyn R, Shavelle D, et al. *Circulation.* 2017;135:1509-17.

### Pressure Changes Stratified by Baseline PA Pressure

**Figure 15.** CHAMPION control cohort

**Figure 16.** CHAMPION treatment cohort

**Figure 17.** General-use cohort



— Baseline Mean PA Pressure < 25 mmHg    — 35 mmHg > Baseline Mean PA Pressure ≥ 25 mmHg    — Baseline Mean PA Pressure ≥ 35 mmHg

Greatest reduction in mean PA pressure observed for CardioMEMS™ HF System patients with higher baseline PA pressure. Patients in the treatment group with baseline PA pressure at goal, remained at goal over time.

Heywood JT, Jermyn R, Shavelle D, et al. *Circulation.* 2017;135:1509-17.

### KEY TAKEAWAYS:

- High transmission compliance.
- Data drove appropriate patient care.
- Same results in HFpEF and HFrEF.
- "Long-term patient acceptance and adherence is clearly demonstrated."
- "The magnitude of pressure lowering ... was significantly larger than was seen in the pivotal clinical trial."

## AMBULATORY HEMODYNAMIC MONITORING REDUCES HEART FAILURE HOSPITALIZATIONS IN "REAL-WORLD" CLINICAL PRACTICE

Desai AS, et al. *JACC.* 2017.[31]

**Real-world Use of the CardioMEMS™ HF System: Reduced Heart Failure Hospitalization and Associated Costs in a Large Retrospective Cohort (n = 1114) from a Medicare Claims Database — 6 and 12 Months of Follow-up**

**Figure 18.** Cumulative heart failure hospitalization during period before and after CardioMEMS™ PA Sensor implant





### KEY TAKEAWAYS:

- Real-world reduction in heart failure hospitalization after CardioMEMS™ PA Sensor implant:
  - 45% reduction at six months.
- Significant cost reductions for hospitalization:
  - $10,510 per patient — six months.
  - $13,190 per patient — year.

These benefits support the real-world effectiveness of this approach to heart failure management.

## ASSOCIATION OF AMBULATORY HEMODYNAMIC MONITORING WITH CLINICAL OUTCOMES IN A CONCURRENT MATCHED COHORT ANALYSIS

Abraham J, et al. *JAMA Cardiology.* 2019.[32]

### STUDY OBJECTIVE:

This study examined the impact of ambulatory hemodynamic monitoring on clinical outcomes in patients with heart failure, asking the following questions:

- Is ambulatory hemodynamic monitoring associated with differences in rates of survival or heart failure hospitalization in a non-trial setting?

- Are results sustained at 12 months?

**Figure 19.** Time series of heart failure hospitalizations in the 12 months before PA pressure sensor implant



| No. at Risk | | | | | |
|---|---|---|---|---|---|
| Control Cohort | 1087 | 1087 | 1087 | 1087 | 1087 |
| Treatment Cohort | 1087 | 1087 | 1087 | 1087 | 1087 |

The cumulative pre-implant heart failure hospitalization events clearly show similar trajectories for both arms of the study leading up to CardioMEMS PA Sensor implantation for the treatment group.

**Figure 20.** Cumulative events after PA pressure sensor implant

**A.** Cumulative heart failure hospitalizations after PA pressure sensor implantation



| No. at Risk | | | | | | |
|---|---|---|---|---|---|---|
| Control Cohort | 1087 | 1000 | 931 | 891 | 850 | 805 | 764 |
| Treatment Cohort | 1087 | 1037 | 991 | 944 | 908 | 862 | 830 |

Cumulative incidence of heart failure hospitalization during 12-month follow-up shows a **24% reduction in heart failure hospitalization rate** in the treatment (CardioMEMS PA Sensor) arm, p < 0.001.

**B.** Kaplan-Meier survival analysis in the matched population



HR 0.70 (95% CI 0.59–0.83)
p < 0.001

Control Cohort
Treatment Cohort

**30%**

Reduction
in Mortality

Probability (%) — Time since Implant (month)

No. at Risk

| | 0 | 2 | 4 | 6 | 8 | 10 | 12 |
|---|---|---|---|---|---|---|---|
| Control Cohort | 1087 | 1000 | 931 | 891 | 850 | 805 | 764 |
| Treatment Cohort | 1087 | 1037 | 991 | 944 | 908 | 862 | 862 |

Kaplan-Meier survival analysis during the 12-month follow-up period shows a **30% reduction in mortality** in the treatment (CardioMEMS™ PA Sensor) arm, p < 0.001.

**C.** Combined outcome of heart failure hospitalization or death



HR 0.73 (95% CI 0.64–0.84)
p < 0.001

Control Cohort
Treatment Cohort

**27%**

Reduction in Heart Failure
Hospitalization or Death

Heart Failure Hospitalization or Death per Patient (y) — Time since Implant (month)

No. at Risk

| | 0 | 2 | 4 | 6 | 8 | 10 | 12 |
|---|---|---|---|---|---|---|---|
| Control Cohort | 1087 | 1000 | 931 | 891 | 850 | 805 | 764 |
| Treatment Cohort | 1087 | 1037 | 991 | 944 | 908 | 862 | 830 |

Combined outcomes during the 12-month follow-up period show a **27% reduction in heart failure hospitalizations or death** in the treatment (CardioMEMS PA Sensor) arm, p < 0.001.

**A.** Heart failure hospitalizations. **B.** Deaths **C.** Combined heart failure hospitalizations and death

## CONCLUSION:

In this large, retrospective, Medicare administrative claims analysis, the authors observed:

- Significantly lower rates of all-cause mortality (30%) and heart failure hospitalization (24%) among heart failure patients implanted with a CardioMEMS™ PA Sensor versus a contemporary cohort of matched controls (p < 0.001 for each).

- Reduced rates of heart failure hospitalization and mortality for CardioMEMS™ HF System patients are similar to outcomes from the CHAMPION trial, even though patients in this study are significantly older.

- Meaningful reductions in the number of days lost to death or hospitalization (17.5–18.5 days), a metric that is meaningful to patients, physicians and payers.

## MONITORING PULMONARY ARTERIAL HYPERTENSION USING AN IMPLANTABLE HEMODYNAMIC SENSOR

Benza, et al. *Chest*. 2019.[33]

### STUDY OBJECTIVE:

Pilot study (N = 26) designed to evaluate the feasibility and early safety of monitoring patients with PAH and right-sided heart failure using the CardioMEMS™ HF System. **Note:** The objective of this pilot study was to test the feasibility of monitoring therapy, not necessarily to use the CardioMEMS HF System to guide the therapy.

### KEY RESULTS:

Significant reductions in PA pressures ($PAP_m$, 42 ± 13 to 34 ± 14 mmHg) and elevations in CO (5.8 ± 1.5 to 6.8 ± 1.8 L/min) were observed over one year of CardioMEMS HF System-monitored therapy. There were also observed elevations in SV, vascular compliance, SVi and Eff, as well as reductions in SW and TPR.

**Figure 21.** Hemodynamic response measured by the CardioMEMS™ HF System for patients at Allegheny General Hospital. Plots show mean ± SE. Asterisks show statistically significant differences ($p < 0.05$) from 0-month baseline. Number of patients at each time point is shown below the x-axes.

In the AUC analyses shown below, SV, TPR and compliance all exhibited significant changes at 12 months relative to baseline ($p < 0.05$). In patients that were highly managed (nine or more medication changes) within the first 4 months (most with serial changes in parenteral prostacyclins, based on knowledge of hemodynamics), early hemodynamic changes were well-visualized and captured using the CardioMEMS™ HF System. Therefore, home monitoring and capturing significant changes in hemodynamic responses to changes in drug therapy over time are feasible.

**Figure 22.** Cumulative hemodynamic response illustrated by AUC analyses across 365 days for patients at Allegheny General Hospital

*$PAP_m$, TPR, SV and compliance are shown as mean (solid line) ± SE of the cumulative change over time. All p < 0.05 at 12 months, relative to baseline.*



Changes in NYHA Class from baseline ($p < 0.001$), natriuretic peptides ($p < 0.01$) and Minnesota Living with Heart Failure Questionnaire quality of life score ($p < 0.001$) for the implanted cohort with at least one-month follow-up post-implant (n = 24) were all encouraging. These improvements mirrored the hemodynamic changes illustrated in the figures above. In addition, 6MWD correlated with CardioMEMS HF System-determined hemodynamics.

These changes were analyzed to demonstrate potential alternative efficacy endpoints that could be used in future trials of the device in PAH and to visualize the parallel between patterned hemodynamic changes obtained through monitoring with the CardioMEMS HF System and other outcomes assessed in clinic.

The case example below shows early clinical worsening for a patient weeks prior to a heart failure hospitalization and subsequent hemodynamic recovery.

**Figure 23.** Example of acute right ventricular failure because of medication noncompliance. Patient medication noncompliance (blue shading) resulted in rise in deteriorating hemodynamics and heart failure hospitalization (orange shading). IV diuresis and reinstitution of medications (red shading) resulted in an improvement in all parameters.



## KEY TAKEAWAYS:

- PAH is a progressive chronic disease that ultimately progresses to right heart failure and death.

- This feasibility study of 26 patients with PAH indicates that the CardioMEMS™ HF System can be used to monitor and effect favorable changes in hemodynamics, and may help guide medical therapy in these patients, resulting in improved outcomes.

- Improvements in patients' hemodynamics correlated with improvements in NYHA functional class, natriuretic peptide levels, quality of life and 6MWD.

- Use of the CardioMEMS HF System in this pilot study was associated with short- and long-term safety.

## CONCLUSION:

The CardioMEMS HF System provided useful information to monitor PAH therapy, and demonstrated short- and long-term safety. Larger clinical trials are needed before its widespread use to guide therapy in patients with severe PAH with right-sided heart failure.

## HEMODYNAMIC-GUIDED MANAGEMENT OF HEART FAILURE (GUIDE-HF)

Lindenfeld, et al. *Am Heart J.* 2019.[34]

- Largest trial ever (N = 3600) to study hemodynamic-guided heart failure management.

- Includes patients currently indicated for the CardioMEMS™ HF System, as well as heart failure patients with NYHA Class II and IV, and heart failure patients with elevated natriuretic peptides without recent heart failure hospitalization.

- Randomized arm (N = 1000) to evaluate the effects of the CardioMEMS HF System on heart failure hospitalization and death, as well as quality of life and functional capacity in NYHA Class II–IV patients with a heart failure hospitalization in the past 12 months or elevated natriuretic peptide levels in the previous 30 days, regardless of left ventricular ejection fraction.

- Single arm (N = 2600) to determine whether PA pressure-guided care is as effective in NYHA Class III patients enrolled based on elevated natriuretic peptide levels as it is in those with a prior heart failure hospitalization.

- Secondary endpoints: Cumulative heart failure event rates 12 months post-implant versus heart failure event rates 12 months pre-implant.

- Positive results will help lead to entry into ACC and AHA heart failure guidelines and obtain CMS National Coverage Determination.

**Figure 24.**



GUIDE-HF Trial Schematic

# Healthcare Economics

## HEALTH ECONOMIC IMPACT OF A PULMONARY ARTERY PRESSURE SENSOR FOR HEART FAILURE TELEMONITORING: A DYNAMIC SIMULATION

Kolominsky-Rabas PL, et al. *Telemedicine and e-Health*. 2016.[35]

### SUMMARY:

This simulation estimated the reductions of heart failure hospitalizations with PA guided care, the improvement on quality of life and the economic savings as a result of implementation in the German healthcare system. This simulation also showed the rise of heart failure prevalence numbers in the context of an aging population, and given the considerable burden of heart failure, the potential of a PA pressure monitoring system to improve the management of heart failure patients and enable cost savings at the same time is substantial.

## PULMONARY ARTERY PRESSURE-GUIDED HEART FAILURE MANAGEMENT: US COST-EFFECTIVENESS ANALYSES USING THE RESULTS OF THE CHAMPION CLINICAL TRIAL

Martinson M, et al. *European J Heart Failure*. 2017.[36]

### KEY RESULTS:

The primary effectiveness endpoint was the ICER comparing the costs and QALYs of heart failure hospitalization outcomes in the CHAMPION treatment and control groups. The model was used to extrapolate this endpoint to five years.

Over the five-year projections, patients in the treatment group had average QALYs of 2.56 with a total cost of $140,966; patients in the control group had QALYs of 2.16 with a total cost of $133,681. The ICER was $18,515 per QALY **(Table 3)**.

### CONCLUSION:

This study, based on the results of the CHAMPION clinical trial, used standard economic modelling to show that PA pressure-guided management of heart failure using the CardioMEMS™ HF System is cost-effective from the perspective of U.S. payers. The ICERs, when considered for heart failure management or comprehensive management, were well below the conventional U.S. acceptability threshold of $50,000.

**Table 3.** Cost-effectiveness analysis base case and survival over a five-year time horizon

| | Primary CEA Endpoint: Heart Failure Hospitalization Outcomes | | All-cause Hospitalization Outcomes | | Comprehensive Patient Management Outcomes | |
|---|---|---|---|---|---|---|
| | Treatment Group | Control Group | Treatment Group | Control Group | Treatment Group | Control Group |
| Cumulative average cost | U.S. $56,974 | U.S. $52,149 | U.S. $140,966 | U.S. $133,681 | U.S. $212,004 | U.S. $200,360 |
| Cumulative QALYs | 2.56 | 2.16 | 2.56 | 2.16 | 2.56 | 2.16 |
| Cumulative average years of survival | 3.70 | 3.47 | 3.70 | 3.47 | 3.70 | 3.47 |
| ICER (U.S. $/QALY) | U.S. $12,262 | | U.S. $18,515 | | U.S. $29,592 | |
| Cost reduction for each patient under treatment post implant (U.S. $/year)[a] | U.S. $4,443 | | U.S. $5,261 | | U.S. $5,296 | |

a. Costs saving per life year for the treatment group.

## COST-EFFECTIVENESS OF REMOTE CARDIAC MONITORING WITH THE CARDIOMEMS HEART FAILURE SYSTEM

Schmier, et al. *Clinical Cardiology*. 2017.[37]

### KEY RESULTS:

Mortality trends are lower for the CardioMEMS™ HF System vs. SOC:

- Based on the model's base case, half (50.4%) of the original CardioMEMS HF System patients were dead at 60 months vs. 50% mortality at 40 months for patients on SOC.

- At the end of the 60 months, 49.6% of CardioMEMS HF System patients remained alive vs. 23.8% of SOC patients.

Cost/QALY was in the high-value space:

- Device cost/QALY was well below $50,000, remaining in the high-value space (based on ACC and AHA guidelines).

### CONCLUSION:

- The CardioMEMS HF System was found to be cost-effective, with an ICER of $44,832 per QALY.

- This places the CardioMEMS HF System in the high-value category compared to LVADs ($128K–$209K/QALY) and CRT-D ($62K/QALY).

- "For heart failure patients meeting current indications, the CardioMEMS HF System may represent an important clinical advance, while at the same time being a cost-effective treatment for heart failure."

**Table 4.** Model results: base case

| | CardioMEMS™ | SOC |
|---|---|---|
| **Five-year costs and outcomes** | | |
| Total costs | $188,880 | $162, 772 |
| Implant: device, procedure, complications | $19,111 | $0 |
| Inpatient costs | $108,124 | $113,199 |
| Outpatient costs (including monitoring) | $61,645 | $49,573 |
| Total accumulated QALYs | 2.509 | 1.926 |
| ICER (cost per QALY gained) | $44,832 | |

**Table 5.** Base case input parameters: costs

| Parameter | Cost (USD)[a] | Source(s) |
|---|---|---|
| CardioMEMS™ device (per device) | $17,750 | Average sales price |
| Implantation procedure | $1,280 | Medicare: $1,138; CPT[‡] 93451, 93568, 33210, 2016 MFS; Commercial: $1,707 (MFS × 1.5) |
| Complications, each | $5,770 | Martinson et al[36] inflated to 2016 |
| Hospitalizations | | Takes into account % Medicare vs. commercial |
| Heart failure hospitalization | $21,007 | Martinson et al[36] inflated to 2016 |
| Non-heart failure hospitalization | $24,367 | Martinson et al[36] inflated to 2016 |
| Monthly monitoring | $47 | Martinson et al[36] inflated to 2016 |
| Outpatient costs, routine care (per year) | $19,576 | Martinson et al[36] inflated to 2016 |

a. Costs are presented in 2016 dollars and were inflated or discounted as described in the methods. All costs are weighted based on the assumption that 75% of patients are covered by Medicare and 25% have commercial coverage.

## THE COST-EFFECTIVENESS OF REAL-TIME PULMONARY ARTERY PRESSURE MONITORING IN HEART FAILURE PATIENTS: A EUROPEAN PERSPECTIVE

Cowie MR, et al. *European Journal of Heart Failure*. 2017.[38]

### STUDY OBJECTIVE:

Heart failure treatment guided by physicians using the CardioMEMS HF System has been shown to reduce heart failure hospitalizations, but uncertainty remains regarding the value of the CardioMEMS HF System in European health systems where healthcare costs are significantly lower than in the United States.

### METHODS:

A Markov model was developed to estimate the cost-effectiveness of PAP-guided treatment of heart failure using the CardioMEMS HF System compared with usual care. Cost-effectiveness was measured as the incremental cost per QALY gained.

### KEY RESULTS:

- In the base case analysis over a time horizon of 10 years, PAP-guided heart failure therapy increased cost compared with usual care by £10,916 (€14,030) (i.e., from £6,189 in usual care to £17,104 in PAP-guided heart failure therapy).

- QALYs per patient for usual care and PAP-guided patients were 2.57 and 3.14, respectively, an increase of 0.57 QALY with PAP-guided treatment.

- The resultant ICER is £19,274 (€24,772) per QALY gained.

- The base case analysis did not include staff time due to a lack of data.

- Running the model with estimated staff time included resulted in an increased ICER of between £22,342 and £25,464 per QALY gained (€28,709–€32,721).

### CONCLUSION:

The analysis indicates that the CardioMEMS HF System could provide a cost-effective means for heart failure physicians to manage and treat patients outside of face-to-face clinic appointments, shifting care from the hospital/clinic to the home, reducing resource-intensive hospitalizations and improving the quality of life of patients suffering from heart failure.

# Post-approval Study

## REDUCTION OF HF HOSPITALIZATION IN THE CARDIOMEMS™ HF SYSTEM POST-APPROVAL STUDY

Raval, et al. Presented at: HFSA 2017.[39]

**Figure 25.**



In the post-approval study, there were 56 heart failure hospitalizations (0.20 events/pt-6m) in 43 pts.

## MEDICATION CHANGES SIGNIFICANTLY REDUCED IN FIRST 90 DAYS VS. SECOND 90 DAYS IN THE PAS

**Figure 26.** Medication changes — first 90 days vs. second 90 days



65% of the overall heart failure medication changes were made in the first 90 days, with trends of stabilization and significantly fewer medication changes during the second 90 days.

**Figure 27.** The CardioMEMS™ HF System PAS short-term results: REDUCED heart failure hospitalization and MEAN PA pressure



| AUC (mmHg day) | | | |
|---|---|---|---|
| | **1 Month** | **3 Months** | **6 Months** |
| CHAMPION control (275 pts) | 3.1 ± 6.7 (270 pts) | -5.5 ± 24.7 (251 pts) | 42.2 ± 65.0 (228 pts) |
| CHAMPION treatment (270 pts) | -7.0 ± 7.7 (266 pts) | -59.3 ± 27.6 (257 pts) | -150.1 ± 71.0 (236 pts) |
| PAS (300 pts) | -27.7 ± 7.0 (291 pts) | -112.6 ± 26.0 (275 pts) | -281.0 ± 63.5 (262 pts) |

**Significantly greater reductions in mean PA pressure** for the PAS cohort relative to the CHAMPION control group after six months, and **qualitatively greater reductions** compared to the CHAMPION treatment group.

# Clinical Research Papers by Topic

## IMPROVED QUALITY OF LIFE AND FUNCTIONAL CAPACITY

- Alam A, Jermyn R, Joseph M, Patel S, Jorde U, Saeed O. Improved quality of life scores and exercise capacity with remote pulmonary artery pressure monitoring in patients with chronic heart failure. *Journal of the American College of Cardiology*. 2016;67(13):1299.

- Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. *The Lancet*. 2016;387(10017):453-461.

## DECREASED HEART FAILURE HOSPITAL ADMISSIONS AND READMISSIONS

- Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. *The Lancet*. 2011;377(9766):658-666.

- Adamson, et al. Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions. *Circulation: Heart Failure*. 2016;115.002600.

- Desai AS, et al. Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in "Real-World" Clinical Practice. *JACC*. 2017;69(19):2357-2365.

- Abraham J, et al. Association of Ambulatory Hemodynamic Monitoring with Clinical Outcomes in a Concurrent Matched Cohort Analysis. *JAMA Cardiology*. 2019;4(6):556-563.

## OPTIMIZED MANAGEMENT IN HFpEF

- Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. *Circulation: Heart Failure*. 2014;7(6):935-944.

## DECREASED PA PRESSURES

- Heywood JT, Jermyn R, Shavelle D, et al. Impact of practice-based management of PA pressures in 2000 patients implanted with the CardioMEMS sensor. *Circulation*. 2017;135:1509-17.

- Raval N, et al. Reduction of HF Hospitalization in the CardioMEMS™ HF System Post-Approval Study. Presented at: HFSA 2017.

## THE CARDIOMEMS™ HF SYSTEM IS PROACTIVE AND ACTIONABLE; GDMT IS REACTIVE AND INEXACT

- Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. *Current Heart Failure Reports*. 2009;6:287-292.

- van Veldhuisen DJ, Braunschweig F, Conraads V, Ford I, Cowie MR, Jondeau G, on behalf of the DOT-HF Investigators. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. *Circulation*. 2011;124:1719-1726.

- Abraham WT, Jermyn R, Shavelle D, Bimaraj A, Bhatt K, Sheikh F, et al. First 2000 CardioMEMS Patients: Pulmonary Artery Pressures Decrease over Time during Heart Failure Management Guided by Ambulatory Hemodynamic Monitoring in Real World Setting. *Journal of Cardiac Failure*. 2016;22(8):S8.

## REHOSPITALIZATION = INCREASED MORTALITY

- Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA. Long-term survival after heart failure: a contemporary population-based perspective. *Archives of Internal Medicine*. 2007;167:490-496.

- Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. *Nature Reviews Cardiology*. 2011;8(1):30-41.

## REDUCED MORTALITY

- Givertz MM, Stevenson LW, et al. Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction. *JACC*. 2017;70:1875-86.

- Abraham J, et al. Association of Ambulatory Hemodynamic Monitoring with Clinical Outcomes in a Concurrent Matched Cohort Analysis. *JAMA Cardiology*. 2019;4(6):556-563.

## PATIENT SELECTION AND WORKFLOW

- Adamson White Paper (on Map).

- Lisa Rathman, Lancaster General: HFSA Abstract — Holding Up Both Ends of the Bargain: Ambulatory Hemodynamic Monitoring Using CardioMEMS.

## REIMBURSEMENT/HEALTHCARE ECONOMICS/REDUCED HOSPITALIZATION COSTS

- Kolominsky-Rabas PL, et al. Health economic impact of a pulmonary artery pressure sensor for heart failure telemonitoring: A dynamic simulation. *Telemedicine and e-Health*. 2016;22:1-11.

- Martinson M, Bharmi R, Dalal N, Abraham WT, Adamson PB. Pulmonary artery pressure guided heart failure management in chronic heart failure: US cost-effectiveness analyses using the results of the CHAMPION Clinical Trial. *European Journal Heart Failure*. 2017;19:652-660.

- Schmier JK, Ong KL, Fonarow GC. Cost-Effectiveness of Remote Cardiac Monitoring with the CardioMEMS Heart Failure System. *Clinical Cardiology*. 2017;40:430-436.

- Desai AS, et al. Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in "Real-World" Clinical Practice. *JACC*. 2017;69(19):2357-2365.

- Cowie MR, Simon M, Klein L, Thokala P. The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective. *European Journal of Heart Failure*. 2017;19:661-669.

## ACRONYM DEFINITIONS

| | | | |
|---|---|---|---|
| 6MHW | six-minute hall walk | bpm | beats per minute |
| 6MWD | six-minute walk distance | CEA | cost-effectiveness analyses |
| ACC | American College of Cardiology | CI | confidence interval |
| ACEI | angiotensin-converting enzyme inhibitor | CKD | chronic kidney disease |
| AF | atrial fibrillation | CMS | Centers for Medicare & Medicaid Services |
| ARB | angiotensin receptor blocker | CO | cardiac output |
| AUC | area under curve | comp | compliance |
| BB | beta blocker | COPD | chronic obstructive pulmonary disease |
| BL | baseline | | |
| | | CPT‡ | Current Procedural Terminology |

| | | | |
|---|---|---|---|
| CRT | cardiac resynchronization therapy | MI | myocardial infarction |
| | | mmHg | millimeter of mercury |
| CRT-D | cardiac resynchronization therapy defibrillator | NYHA | New York Heart Association |
| | | PA | pulmonary artery |
| EF | ejection fraction | PAH | pulmonary arterial hypertension |
| Eff | right ventricular efficiency | PAP | pulmonary artery pressure |
| EPPY | events per patient-year | PAP$_d$ | diastolic pulmonary artery pressure |
| GDMT | guideline-directed medical therapy | | |
| | | PAP$_m$ | mean pulmonary artery pressure |
| GDP | gross domestic product | PAP$_s$ | systolic pulmonary artery pressure |
| GUIDE-HF | Hemodynamic-GUIDEd Management of Heart Failure | | |
| | | PAS | post-approval study |
| HF | heart failure | PH | pulmonary hypertension |
| HFpEF | heart failure with preserved ejection fraction | pts | points |
| | | QALY | quality-adjusted life year |
| HFrEF | heart failure with reduced ejection fraction | RA | randomized access |
| | | rEF | reduced ejection fraction |
| HR | hazard ratio | REH | respiratory event hospitalization |
| ICD | implantable cardioverter defibrillator | RHC | right heart catheterization |
| | | RRR | relative risk reduction |
| ICER | incremental cost-effectiveness ratio | SE | shaded envelope |
| | | SOC | standard of care |
| IDE | investigational device exemption | SV | right ventricular stroke volume |
| IV | intravenous | SVi | stroke volume index |
| KCCQ | Kansas City Cardiomyopathy Questionnaire | SW | right ventricular stroke work |
| | | SWi | stroke work index |
| LVAD | left ventricular assist device | TPG | transpulmonary gradient |
| LVEF | left ventricular ejection fraction | TPR | total pulmonary resistance |
| MFS | Medicare Fee Schedule | VAD | ventricular assist device |
| | | WHO | World Health Organization |

1. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. *The Lancet*. 2011;377(9766):658-666.

2. Adamson, et al. Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions. *Circulation: Heart Failure*. 2016;115.002600.

3. Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, et al. Telemonitoring in patients with heart failure. *The New England Journal of Medicine*. 2010;363:2301-2309.

4. Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Böhm M. Telemedical Interventional Monitoring in Heart Failure Investigators. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: The Telemedical Interventional Monitoring in Heart Failure study. *Circulation*. 2011;123:1873-1880.

5. Abraham WT, Compton S, Haas G, Foreman B, Canby RC, Fishel R., on behalf of the FAST Study Investigators. Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). *Congestive Heart Failure*. 2011;17:51-55.

6. Conraads VM, Tavazzi L, Santini M, Oliva F, Gerritse B, Yu CM, et al. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. *European Heart Journal*. 2011;32:2266-2273.

7. Whellan DJ, Ousdigian KT, Al-Khatib SM, Pu W, Sarkar S, Porter CB., on behalf of the PARTNERS Study Investigators. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study. *Journal of the American College of Cardiology*. 2010;55:1803-1810.

8. van Veldhuisen DJ, Braunschweig F, Conraads V, Ford I, Cowie MR, Jondeau G, on behalf of the DOT-HF Investigators. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. *Circulation*. 2011;124:1719-1726.

9. Verdejo HE, Castro PF, Concepción R, Ferrada MA, Alfaro MA, Alcaíno ME, et al. Comparison of a radiofrequency-based wireless pressure sensor to Swan-Ganz catheter and echocardiography for ambulatory assessment of pulmonary artery pressure in HF. *Journal of the American College of Cardiology*. 2007;50:2375-23782.

10. Abraham WT, Adamson PB, Hasan A, Bourge RC, Pamboukian SV, Aaron MF, et al. Safety and accuracy of a wireless pulmonary artery pressure monitoring system in patients with heart failure. *American Heart Journal*. 2011;161:558-566.

11. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. *The Lancet*. 2016;387(10017):453-461.

12. Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. *Circulation: Heart Failure*. 2014;7(6):935-944.

13. Givertz MM, Stevenson LW, et al. Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction. *JACC*. 2017;70:1875-86.

14. Weiner S, Abraham WT, Adamson PB, Neville S, Henderson J. Effect of CRT on heart failure related
hospitalizations in patients with reduced EF utilizing remote pulmonary artery pressures in the CHAMPION trial. *Heart Rhythm*. 2011;8(5S):S437.

15. Strickland WL, Parrott CW, Abraham WT, Adamson PB, Corcoran K, Cowart P, et al. The utility of remote wireless pulmonary artery pressure monitoring in patients with or without a history of myocardial infarction: experience from the CHAMPION trial. *Journal of the American College of Cardiology*. 2011;58(20 Supplement):B130.

16. Miller AB, Teerlink J, Carson P, Levy W, Chung E, Gilbert E, et al. Impact of remote, wireless pulmonary artery hemodynamic monitoring in patients with atrial fibrillation and chronic heart failure: insights from the CHAMPION trial. *Journal of the American College of Cardiology*. 2012;59(13 Suppl):E868.

17. Adamson PB, Abraham WT, Stevenson L, Bourge R, Raval N, Bauman J, et al. Targeting pulmonary artery pressures in the treatment of chronic heart failure: insights from the CHAMPION trial. *European Heart Journal*. 2012;33(Abstract Suppl):650-651.

18. Abraham WT, Adamson PB, Stevenson LW, Yadav J. Benefits of pulmonary artery pressure monitoring in patients with NYHA class III heart failure and chronic kidney disease: results from the CHAMPION trial. *Journal of Cardiac Failure*. 2014;20(8):S93.

19. Benza RL, Raina A, Abraham WT, Adamson PB, Lindenfeld J, Miller AB, et al. Pulmonary hypertension related to left heart disease: Insight from a wireless implantable hemodynamic monitor. *The Journal of Heart and Lung Transplantation*. 2015;34(3):329-337.

20. Krahnke JS, Abraham WT, Adamson PB, Bourge RC, Bauman J, Ginn G, et al. Heart failure and respiratory hospitalizations are reduced in heart failure subjects with chronic obstructive pulmonary disease using an implantable pulmonary artery pressure monitoring device. *J Card Fail*. 2015;21:240-249.

21. Raina A, Abraham WT, Adamson PB, Bauman J, Benza RL. Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease: insights from a wireless pulmonary artery pressure monitoring system. *J Heart and Lung Transplant*. 2015;34(3):438-447.

22. Goldberg LR, Desai AS, Costanzo MR, Stevenson LW, Adamson PB, Heywood JT, et al. Pressure for action: implantable pulmonary artery pressure sensor measurements alone beat clinical signs to guide prevention of heart failure hospitalizations. 2015;Abstract AB36-02 presented at HRS 2015, Boston.

23. Costanzo MR, Stevenson LW, Adamson PB, et al. Interventions Linked to Decreased Heart failure hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring. *JACC Heart Fail*. 2016;4:333-344.

24. Lang CC, Mancini DM. Management of comorbidities in heart failure. 2008. London: Springer.

25. Abraham WT, Adamson PB, Stevenson LW, Costanzo MR, Bourge RC, Bauman J, et al. Pulmonary artery pressure management in heart failure patients with cardiac resynchronization therapy or implantable cardioverter defibrillator devices significantly reduces heart failure hospitalizations and mortality above and beyond background guide-directed medical therapy. 2015;Abstract AB37-03 presented at HRS 2015, Boston.

26. Criner G, et al. Impact of wireless implanted pulmonary artery pressure monitoring system in heart failure patients with comorbid chronic obstructive pulmonary disease. *Eur Resp J*. 2012;40(Suppl 56):P9761.

27. Martinez F, et al. Respiratory event hospitalizations are reduced in heart failure patients with comorbid chronic obstructive pulmonary disease using a wireless implanted pulmonary artery pressure monitoring system. *Eur Resp J*. 2012;40(Suppl 56):2832.

28. Feldman D, Moazami N, Adamson PB, Vierecke J, Raval N, Shreenivus S, et al. The utility of a wireless implantable hemodynamic monitoring system in patients requiring mechanical circulatory support. *ASAIO*. 2018;64:301-308.

29. Jermyn R, Alam A, Kvasic J, Saeed O, Jorde U. Hemodynamic-guided heart-failure management using a wireless implantable sensor: Infrastructure, methods, and results in a community heart failure disease-management program. *Clin Cardiol*. 2016. doi: 10.1002/clc.22643

30. Heywood JT, Jermyn R, Shavelle D, et al. Impact of practice-based management of PA pressures in 2000 patients implanted with the CardioMEMS sensor. *Circulation*. 2017;135:1509-17.

31. Desai AS, et al. Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in "Real-World" Clinical Practice. *JACC*. 2017;69(19):2357-2365.

32. Abraham J, et al. Association of Ambulatory Hemodynamic Monitoring with Clinical Outcomes in a Concurrent Matched Cohort Analysis. *JAMA Cardiology*. 2019;4(6):556-563.

33. Benza RL, et al. Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor. *Chest*. 2019;156(6):1176-1186.

34. Lindenfeld J, et al. Hemodynamic-GUIDEd Management of Heart Failure (GUIDE-HF). *Am Heart J*. 2019;214:18-27.

35. Kolominsky-Rabas PL, et al. Health economic impact of a pulmonary artery pressure sensor for heart failure telemonitoring: A dynamic simulation. *Telemedicine and e-Health*. 2016;22:798-808.

36. Martinson M, Bharmi R, Dalal N, Abraham WT, Adamson PB. Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial. *European Journal Heart Failure*. 2017. doi:10.1002/ejhf.642.

37. Schmier JK, Ong KL, Fonarow GC. Cost-Effectiveness of Remote Cardiac Monitoring with the CardioMEMS Heart Failure System. *Clinical Cardiology*. 2017;40:430-436.

38. Cowie MR, Simon M, Klein L, Thokala P. The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective. *European Journal of Heart Failure*. 2017;19:661-669.

39. Raval N, et al. Significant Reductions in Heart Failure Hospitalizations with the Pulmonary Artery Pressure Guided HF System: Preliminary Observations From the CardioMEMS Post Approval Study. Presented at: HFSA 2017.

**Rx Only**

**Brief Summary:** Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

**Indications and Usage:** The CardioMEMS™ HF System is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in New York Heart Association (NYHA) Class III heart failure (HF) patients who have been hospitalized for heart failure in the previous year. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations.

**Contraindications:** The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one-month post implant.

**Potential Adverse Events:** Potential adverse events associated with the implantation procedure include, but are not limited to, the following: Infection, Arrhythmias, Bleeding, Hematoma, Thrombus, Myocardial infarction, Transient ischemic attack, Stroke, Death, and Device embolization.

™ Indicates a trademark of the Abbott group of companies.
‡ Indicates a third party trademark, which is property of its respective owner.

Abbott